We have observed
8 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after April 20, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
TOPICAL LOCALIZED ISOXAZOLINE FORMULATION COMPRISING GLYCOFUROL
INJECTABLE FORMULATION OF A MACROCYCLIC LACTONE AND LEVAMISOLE
TREATMENT OF MASTITIS
PARASITICIDAL COMBINATION COMPRISING INDOXACARB AND DELTAMETHRIN
USE OF LIQUID MEDIUM EXCHANGE BY CROSS FLOW FILTRATION IN THE PREPARATION OF DRUG SUSPENSIONS
SOFT CHEWABLE PHARMACEUTICAL PRODUCTS
SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS
Pharmaceutical transdermal compositions and method for treating inflammation in cattle